Cargando…
Short-term mechanical support with the Impella 5.x for mitral valve surgery in advanced heart failure—protected cardiac surgery
INTRODUCTION: Surgical treatment of patients with mitral valve regurgitation and advanced heart failure remains challenging. In order to avoid peri-operative low cardiac output, Impella 5.0 or 5.5 (5.x), implanted electively in a one-stage procedure, may serve as a peri-operative short-term mechanic...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400355/ https://www.ncbi.nlm.nih.gov/pubmed/37547249 http://dx.doi.org/10.3389/fcvm.2023.1229336 |
_version_ | 1785084425877323776 |
---|---|
author | Osswald, Anja Shehada, Sharaf-Eldin Zubarevich, Alina Kamler, Markus Thielmann, Matthias Sommer, Wiebke Weymann, Alexander Ruhparwar, Arjang El Gabry, Mohamed Schmack, Bastian |
author_facet | Osswald, Anja Shehada, Sharaf-Eldin Zubarevich, Alina Kamler, Markus Thielmann, Matthias Sommer, Wiebke Weymann, Alexander Ruhparwar, Arjang El Gabry, Mohamed Schmack, Bastian |
author_sort | Osswald, Anja |
collection | PubMed |
description | INTRODUCTION: Surgical treatment of patients with mitral valve regurgitation and advanced heart failure remains challenging. In order to avoid peri-operative low cardiac output, Impella 5.0 or 5.5 (5.x), implanted electively in a one-stage procedure, may serve as a peri-operative short-term mechanical circulatory support system (st-MCS) in patients undergoing mitral valve surgery. METHODS: Between July 2017 and April 2022, 11 consecutive patients underwent high-risk mitral valve surgery for mitral regurgitation supported with an Impella 5.x system (Abiomed, Inc. Danvers, MA). All patients were discussed in the heart team and were either not eligible for transcatheter edge-to-edge repair (TEER) or surgery was considered favorable. In all cases, the indication for Impella 5.x implantation was made during the preoperative planning phase. RESULTS: The mean age at the time of surgery was 61.6 ± 7.7 years. All patients presented with mitral regurgitation due to either ischemic (n = 5) or dilatative (n = 6) cardiomyopathy with a mean ejection fraction of 21 ± 4% (EuroScore II 6.1 ± 2.5). Uneventful mitral valve repair (n = 8) or replacement (n = 3) was performed via median sternotomy (n = 8) or right lateral mini thoracotomy (n = 3). In six patients, concomitant procedures, either tricuspid valve repair, aortic valve replacement or CABG were necessary. The mean duration on Impella support was 8 ± 5 days. All, but one patient, were successfully weaned from st-MCS, with no Impella-related complications. 30-day survival was 90.9%. CONCLUSION: Protected cardiac surgery with st-MCS using the Impella 5.x is safe and feasible when applied in high-risk mitral valve surgery without st-MCS-related complications, resulting in excellent outcomes. This strategy might offer an alternative and comprehensive approach for the treatment of patients with mitral regurgitation in advanced heart failure, deemed ineligible for TEER or with need of concomitant surgery. |
format | Online Article Text |
id | pubmed-10400355 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104003552023-08-05 Short-term mechanical support with the Impella 5.x for mitral valve surgery in advanced heart failure—protected cardiac surgery Osswald, Anja Shehada, Sharaf-Eldin Zubarevich, Alina Kamler, Markus Thielmann, Matthias Sommer, Wiebke Weymann, Alexander Ruhparwar, Arjang El Gabry, Mohamed Schmack, Bastian Front Cardiovasc Med Cardiovascular Medicine INTRODUCTION: Surgical treatment of patients with mitral valve regurgitation and advanced heart failure remains challenging. In order to avoid peri-operative low cardiac output, Impella 5.0 or 5.5 (5.x), implanted electively in a one-stage procedure, may serve as a peri-operative short-term mechanical circulatory support system (st-MCS) in patients undergoing mitral valve surgery. METHODS: Between July 2017 and April 2022, 11 consecutive patients underwent high-risk mitral valve surgery for mitral regurgitation supported with an Impella 5.x system (Abiomed, Inc. Danvers, MA). All patients were discussed in the heart team and were either not eligible for transcatheter edge-to-edge repair (TEER) or surgery was considered favorable. In all cases, the indication for Impella 5.x implantation was made during the preoperative planning phase. RESULTS: The mean age at the time of surgery was 61.6 ± 7.7 years. All patients presented with mitral regurgitation due to either ischemic (n = 5) or dilatative (n = 6) cardiomyopathy with a mean ejection fraction of 21 ± 4% (EuroScore II 6.1 ± 2.5). Uneventful mitral valve repair (n = 8) or replacement (n = 3) was performed via median sternotomy (n = 8) or right lateral mini thoracotomy (n = 3). In six patients, concomitant procedures, either tricuspid valve repair, aortic valve replacement or CABG were necessary. The mean duration on Impella support was 8 ± 5 days. All, but one patient, were successfully weaned from st-MCS, with no Impella-related complications. 30-day survival was 90.9%. CONCLUSION: Protected cardiac surgery with st-MCS using the Impella 5.x is safe and feasible when applied in high-risk mitral valve surgery without st-MCS-related complications, resulting in excellent outcomes. This strategy might offer an alternative and comprehensive approach for the treatment of patients with mitral regurgitation in advanced heart failure, deemed ineligible for TEER or with need of concomitant surgery. Frontiers Media S.A. 2023-07-11 /pmc/articles/PMC10400355/ /pubmed/37547249 http://dx.doi.org/10.3389/fcvm.2023.1229336 Text en © 2023 Osswald, Shehada, Zubarevich, Kamler, Thielmann, Sommer, Weymann, Ruhparwar, El Gabry and Schmack. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Osswald, Anja Shehada, Sharaf-Eldin Zubarevich, Alina Kamler, Markus Thielmann, Matthias Sommer, Wiebke Weymann, Alexander Ruhparwar, Arjang El Gabry, Mohamed Schmack, Bastian Short-term mechanical support with the Impella 5.x for mitral valve surgery in advanced heart failure—protected cardiac surgery |
title | Short-term mechanical support with the Impella 5.x for mitral valve surgery in advanced heart failure—protected cardiac surgery |
title_full | Short-term mechanical support with the Impella 5.x for mitral valve surgery in advanced heart failure—protected cardiac surgery |
title_fullStr | Short-term mechanical support with the Impella 5.x for mitral valve surgery in advanced heart failure—protected cardiac surgery |
title_full_unstemmed | Short-term mechanical support with the Impella 5.x for mitral valve surgery in advanced heart failure—protected cardiac surgery |
title_short | Short-term mechanical support with the Impella 5.x for mitral valve surgery in advanced heart failure—protected cardiac surgery |
title_sort | short-term mechanical support with the impella 5.x for mitral valve surgery in advanced heart failure—protected cardiac surgery |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400355/ https://www.ncbi.nlm.nih.gov/pubmed/37547249 http://dx.doi.org/10.3389/fcvm.2023.1229336 |
work_keys_str_mv | AT osswaldanja shorttermmechanicalsupportwiththeimpella5xformitralvalvesurgeryinadvancedheartfailureprotectedcardiacsurgery AT shehadasharafeldin shorttermmechanicalsupportwiththeimpella5xformitralvalvesurgeryinadvancedheartfailureprotectedcardiacsurgery AT zubarevichalina shorttermmechanicalsupportwiththeimpella5xformitralvalvesurgeryinadvancedheartfailureprotectedcardiacsurgery AT kamlermarkus shorttermmechanicalsupportwiththeimpella5xformitralvalvesurgeryinadvancedheartfailureprotectedcardiacsurgery AT thielmannmatthias shorttermmechanicalsupportwiththeimpella5xformitralvalvesurgeryinadvancedheartfailureprotectedcardiacsurgery AT sommerwiebke shorttermmechanicalsupportwiththeimpella5xformitralvalvesurgeryinadvancedheartfailureprotectedcardiacsurgery AT weymannalexander shorttermmechanicalsupportwiththeimpella5xformitralvalvesurgeryinadvancedheartfailureprotectedcardiacsurgery AT ruhparwararjang shorttermmechanicalsupportwiththeimpella5xformitralvalvesurgeryinadvancedheartfailureprotectedcardiacsurgery AT elgabrymohamed shorttermmechanicalsupportwiththeimpella5xformitralvalvesurgeryinadvancedheartfailureprotectedcardiacsurgery AT schmackbastian shorttermmechanicalsupportwiththeimpella5xformitralvalvesurgeryinadvancedheartfailureprotectedcardiacsurgery |